In a filing, Kymera Therapeutics Inc revealed its Chief Executive Officer Mainolfi Nello unloaded Company’s shares for reported $2.34 million on Dec 31 ’25. In the deal valued at $78.06 per share,30,000 shares were sold. As a result of this transaction, Mainolfi Nello now holds 663,077 shares worth roughly $49.58 million.
Then, Mainolfi Nello bought 30,000 shares, generating $2,330,700 in total proceeds.
Before that, Esposito Pamela sold 27,563 shares. Kymera Therapeutics Inc shares valued at $2,264,480 were divested by the Director at a price of $82.16 per share. As a result of the transaction, Esposito Pamela now holds 0 shares, worth roughly $0.0.
Wolfe Research downgraded its Kymera Therapeutics Inc [KYMR] rating to a Peer perform from a an Outperform in a research note published recently. B. Riley Securities also remained covering KYMR and reiterated its “Buy” recommendation on October 24, 2025. Mizuho started covering the stock on October 21, 2025. It rated KYMR as “an Outperform”.
Price Performance Review of KYMR
On Monday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock fall -0.28% to $74.77. Over the last five days, the stock has gained 2.76%. Kymera Therapeutics Inc shares have risen nearly 82.72% since the year began. Nevertheless, the stocks have fallen -3.91% over the past one year.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-12-15, dropping by -0.69 million shares to a total of 7.89 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 8.58 million shares. There was a decline of -8.7%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 18, 2025 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $70.
